Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 5/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.48 |
| ▸ | ANO1 | Q5XXA6 | 9/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | WDR5 | P61964 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6119722 | 0.95 | CYP2C9 (0.45) | CYP2C9CYP3A4CYP2C19KCNH2ANO1 | |
| SCHEMBL2302690 | 0.94 | CYP2C9 (0.45) | CYP2C9CYP3A4CYP2C19KCNH2ANO1 | |
| SCHEMBL2298467 | 0.91 | CYP2C9 (0.47) | CYP2C9CYP3A4CYP2C19KCNH2ANO1 | |
| SCHEMBL2298808 | 0.90 | CYP2C9 (0.59) | CYP2C9CYP3A4CYP2C19KCNH2 | |
| SCHEMBL6120327 | 0.90 | CYP2C9 (0.46) | CYP2C9CYP3A4CYP2C19KCNH2ANO1 | |
| SCHEMBL2296799 | 0.90 | CYP2C9 (0.43) | CYP2C9CYP3A4CYP2C19KCNH2ANO1 | |
| SCHEMBL6120266 | 0.89 | CYP2C9 (0.41) | CYP2C9CYP3A4CYP2C19KCNH2ANO1 | |
| SCHEMBL6119280 | 0.89 | TRPV1 (0.40) | CYP2C9CYP3A4CYP2C19KCNH2ANO1 | |
| SCHEMBL6119844 | 0.89 | CYP2C9 (0.50) | CYP2C9CYP3A4CYP2C19KCNH2 | |
| SCHEMBL6120102 | 0.89 | CYP2C9 (0.45) | CYP2C9CYP3A4CYP2C19KCNH2ANO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107567442-B | Inhibitors of hepatitis C virus polymerase | 共晶制药公司 | 2021-05-25 | — | — | CN | disclosed |
| US-10947210-B2 | Inhibitors of Hepatitis C virus polymerase | COCRYSTAL PHARMA, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-20200255393-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL PHARMA, INC. | 2020-08-13 | — | — | US | disclosed |
| US-10464914-B2 | Inhibitors of hepatitis C virus polymerase | COCRYSTAL PHARMA, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| EP-3274340-B1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL PHARMA INC (US) | 2019-07-17 | — | — | EP | disclosed |
| EP-2744342-B1 | THERAPEUTIC METHODS | GLAXOSMITHKLINE LLC (US) | 2019-04-24 | — | — | EP | disclosed |
| US-10238678-B2 | Therapeutic methods | GLAXOSMITHKLINE LLC (US) | 2019-03-26 | — | — | US | disclosed |
| US-20180050998-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL PHARMA, INC. | 2018-02-22 | — | — | US | disclosed |
| EP-3274340-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | Cocrystal Pharma, Inc. (US) | 2018-01-31 | — | — | EP | disclosed |
| EP-3199531-A1 | BENZOFURAN COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS | Glaxo Group Limited (GB) | 2017-08-02 | — | — | EP | disclosed |
| US-7666863-B2 | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases | VIROPHARMA INCORPORATED (US) | 2010-02-23 | — | — | US | disclosed |
| US-20090281336-A1 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | SAHA ASHIS K | 2009-11-12 | — | — | US | disclosed |
| US-20080075695-A1 | COMBINATION THERAPY METHOD FOR TREATING HEPATITIS C VIRUS INFECTION AND PHARMACEUTICAL COMPOSITIONS FOR USE THEREIN | HOWE ANITA Y | 2008-03-27 | — | — | US | disclosed |
| WO-2008024843-A2 | COMBINATION THERAPY METHOD FOR TREATING HEPATITIS C VIRUS INFECTION AND PHARMACEUTICAL COMPOSITIONS FOR USE THEREIN | VIROPHARMA INCORPORATED (US) | 2008-02-28 | — | — | WO | disclosed |
| US-20070231318-A1 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | SAHA ASHIS K | 2007-10-04 | — | — | US | disclosed |
| US-7265152-B2 | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases | VIROPHARMA INCORPORATED (US) | 2007-09-04 | — | — | US | disclosed |
| EP-1581207-A4 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | VIROPHARMA INC (US) | 2007-07-25 | — | — | EP | disclosed |
| EP-1581207-A2 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | Viropharma Incorporated (US) | 2005-10-05 | — | — | EP | disclosed |
| US-20040162318-A1 | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases | VIROPHARMA INCORPORATED | 2004-08-19 | — | — | US | disclosed |
| WO-2004041201-A2 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | VIROPHARMA INCORPORATED (US) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070231318-A1 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | BBOX1, HAVCR2, CYP2E1 | CYP2C9 129/4885CYP3A4 38/4885CYP2C19 117/4885 |
| US-20200255393-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | POLI, POLR2E, POLR2H | CYP2C9 633/4885CYP3A4 437/4885CYP2C19 786/4885 |
| US-10464914-B2 | Inhibitors of hepatitis C virus polymerase | POLI, POLR2E, POLR2H | CYP2C9 633/4885CYP3A4 437/4885CYP2C19 786/4885 |
| US-10238678-B2 | Therapeutic methods | HAVCR2, SLC10A1, OAT | CYP2C9 2142/4885CYP3A4 1989/4885CYP2C19 2218/4885 |
| US-20090281336-A1 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | BBOX1, HAVCR2, CYP2E1 | CYP2C9 129/4885CYP3A4 38/4885CYP2C19 117/4885 |
| US-10947210-B2 | Inhibitors of Hepatitis C virus polymerase | POLI, POLR2E, POLR2H | CYP2C9 633/4885CYP3A4 437/4885CYP2C19 786/4885 |
| US-20040162318-A1 | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases | BBOX1, HAVCR2, CYP2E1 | CYP2C9 129/4885CYP3A4 38/4885CYP2C19 117/4885 |
| US-20180050998-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | POLI, POLR2E, POLR2H | CYP2C9 633/4885CYP3A4 437/4885CYP2C19 786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.